QTRX · Quanterix Corp
$3.39
-0.10 (-2.87%)
At close · Jul 29
Market Cap
$164.40M
Shares
47.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.49
Open$3.62
Day$3.47–3.73
52W$2.40–8.77
Avg vol 30d923K
Short int4.3M · 9.2% float · 9.2d
Short vol37%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
+0%
above
RSI (14)
42
neutral
MACD trend
Negative
52-week position
17%
mid-range
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−46%
trailing
YTD return
−45%
this year
Relative strength
−54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Distributing
29 of 127 funds reported for Jun 30 · net -952.1K sh shares · +11 new
Insider flow
Accumulating
Net +$9.7K over 90 days · 0% sells
Short interest
Rising
9.21% of float · ▲ +0.2% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
127 holders — near 3-yr low, contrarian setup
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
Gross margin
173%
contracting
EPS growth
−151%
Y/Y
Free cash flow
$-79.8M
Balance sheet
$14.6M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
2026
Revenues
Initiated
$169M – $174M
prior FY $138.9M
midpoint +23.5% Y/Y
end of the year
Cash
Initiated
$100M
Guided vs delivered
· last 1 settled
Revenue
2025
guided $130M – $135M
$138.9M
Beat +4.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
+0%
Bullish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Distributing
29 of 127 funds reported for Jun 30 · net -952.1K sh shares · +11 new
Insider flow
Accumulating
Net +$9.7K over 90 days · 0% sells
Short interest
Rising
9.21% of float · ▲ +0.2% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
127 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $2
Now $3 · 17%
52-wk high $9
vs 200-day avg -30%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted cash usage non-GAAP | $14.7M | Q1 2026 | — |
| Adjusted EBITDA (non-GAAP) loss non-GAAP | -$9.8M | Q1 2026 | — |
|
|
|||
| Adjusted gross margin (non-GAAP) non-GAAP | 50.9% | Q1 2026 | — |
| Cash, cash equivalents, marketable securities, and restricted cash | $121.6M | Q4 2025 | — |
| CMS reimbursement rate for LucentAD Complete test | $897 | Full Year 2025 | — |
| Cost savings related to Akoya transaction | $74M | Full Year 2025 | — |
| GAAP gross margin | 46.8% | Full Year 2025 | — |
| Installed instruments | 1,439 | Full Year 2025 | — |
| Integration milestones complete | 94% | Full Year 2025 | — |
| New assays launched | 13 | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QTRX
this stock
Quanterix Corp
|
$164.40M | -45.1% | +64.5% | — | 9.2% |
|
ABT
Abbott Laboratories
|
$186.84B | -13.9% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$132.87B | -1.1% | +11.2% | 40.1 | 1.8% |
|
MDT
Medtronic plc
|
$111.21B | -8.8% | +8.4% | 23.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.43B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QTRX | -10.5% | -19.2% | -46.3% | -19.2% | -45.1% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -9.5% | -19.2% | -53.8% | -18.4% | -53.8% |
Key facts
CIK
1503274
CUSIP
74766Q101
13F (30d)
24 filings
24 filers
Visit website
Investor relations